Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer increases the water dispersibility of the granular composition, and protects the first pesticide against hydrolysis and photolysis.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound.

Abstract: A dosage form article suitable for oral administration, comprising more than one compartments each delimited by a plurality of distinct segments selected from the group consisting of body parts, cap parts and combinations thereof. The dosage form article comprises: at least one first body part and at least one first cap part each comprising inner and outer surfaces, wherein the first body and cap parts are telescopically engageable; and at least one second body part, comprising inner and outer surfaces, being telescopically engageable with the at least one first body or cap parts or both. The at least one of the second body parts is arranged within the at least one first body part or cap part or both such that a distinct first compartment is formed between the outer surface of the second body part and the inner surface of the first body part or cap part or both.

Abstract: Methods and compositions with anti-fouling properties that are derived from lignin are disclosed. The compositions include lignin with one or more zwitterionic functional groups. The lignin with one or more zwitterionic functional groups may be incorporated in paints and coatings to prepare biocidal coatings.

Abstract: Inventive embodiments disclosed herein relate to gel volume mascara. The mascara includes water in a concentration of at least about 45% by weight; disodium ethylenediaminetetraacetate; Polysorbate 20; Black iron oxide; One or more waxes selected from the group consisting of beeswax, Cera Carnauba/Copernicia Cerifera (Carnauba) Wax/CIRE de Carnauba, and paraffin in a concentration of 15-20% by weight; and a synthetic layered silicate, insoluble in water, in a concentration effective for forming a colloidal dispersion with the water.

Abstract: An organopolysiloxane emulsion composition produced by the emulsion polymerization of an emulsion that comprises (A) an organopolysiloxane containing a silanol group or an organooxy group, (B) a nonionic surfactant represented by formula (2): R2O(EO)a(PO)bR3 (wherein R2 represents an alkyl group or R4(CO)—; R4 represents an alkyl group; R3 represents an alkyl group or R5(CO)—; R5 represents an alkyl group; EO represents an ethylene oxide group; PO represents an alkylene oxide group; and a and b independently represent 0 to 100, wherein a+b>0 and the sequence of EO and PO may be random or in the form of a block) and (C) a surfactant other than the component (B), and may additionally comprise (D) a polymerization catalyst and (E) water if required. According to the present invention, it becomes possible to produce an extremely stable organopolysiloxane emulsion composition without inhibiting polymerization during the emulsion polymerization of an organopolysiloxane having condensation reactivity.

Abstract: A novel product for mold prevention and treatment is disclosed herein. The product comprises water, one or more anti-mold agents, one or more water-soluble fluoropolymers or other water-soluble polymers with similar properties, and one or more emulsifiers. In some embodiments, the product may further comprise one or more preservatives, one or more stabilizers, one or more binders, one or more fining agents, one or more firming agents, one or more thickeners, and/or one or more clarifying agents. The product may be non-toxic, biodegradable, effective for a long-period of time and against a wide variety of molds, and may also provide other features which render it safe for the environment as compared to other commonly used products in mold prevention and treatment.

Abstract: A composition for treating and preventing diaper rash comprises zinc oxide, dimethicone, mineral oil, a suspending agent, and an emulsifier. The emulsifier has a Hydrophile-Lipophile Balance number of at most 4.5 and the composition is sprayable. The suspending agent may be a hydrophobic clay.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: The present invention relates to a cosmetic composition for making up and/or caring for the skin and/or the lips, comprising, in a physiologically acceptable medium, at least one oil, which is preferably non-volatile, at least hydrophobic silica aerogel particles, at least one hydrocarbon-based resin having a number-average molecular weight of less than or equal to 10 000 g/mol, the said composition comprising less than 5% by weight of water relative to the total weight of the composition, and preferably being anhydrous.

Abstract: In one embodiment, the invention relates to a method for rendering a non-metallic substrate stably antimicrobial. The method comprises: (a) contacting the substrate with an antimicrobial surfactant; (b) contacting the substrate with a polymeric binder; and (c) subjecting the substrate, surfactant, and binder to conditions at which the substrate becomes stably antimicrobial. In another embodiment, the invention relates to a substrate into which an antimicrobial surfactant and a binder have penetrated.

Abstract: An animal feed such as a milk replacer includes a soluble fiber and a sugar alcohol. The milk replacer enhances weight gain, starter intake and reduces weaning time. The method of feeding the animal includes feeding a mixture of a soluble fiber and sugar alcohol. The animal feed may be used as a method of weaning young ruminants such as calves.

Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.

Abstract: The invention relates to porous granular calcium phosphate osteoinductive materials, particularly materials useful in body tissue repair, principally bone repair and bone replacement, and also to the use of such materials and to a method of making such materials. Exemplary materials comprise discrete porous granules each containing crystals of at least one calcium phosphate, wherein (i) at least 90% of said crystals of the granules have a crystal size in the range 10-100 nm, (ii) at least 90% of the pores in the granules have a pore size in the range 10-500 nm, (iii) the average pore size of the pores having pore size in the range 10-500 nm in the granules is in the range 30-90 nm, (iv) the total volume porosity of the granules is at least 50%, and (v) the surface area of the granules is in the range 10-70 m2/g.

Abstract: Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.

Abstract: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidization device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.

Abstract: An edible product including surimi, fish or fish portions, in various pasta-like shapes. The edible product has a high satiety index relative to unprocessed cooked fish and also provides a low glycemic index when compared to conventional pasta. Also disclosed is a method of manufacturing the edible product in various pasta-like shapes. The product may include between 1%-25% protein, between 1%-20% fat, and a ratio of Omega 3 to Omega 6 of at least 5:1.

Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.